Investor Relations
Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

Media Contact
Rooney & Associates
Terry Rooney
212-223-0689
trooney@rooneyco.com
or
Marion Janic
212-223-4017
mjanic@rooneyco.com

OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder more »

OPKO Health's GeneDx to have Significant Presence at ACMG 2017 more »

OPKO Health to Participate in the Barclays Global Healthcare Conference more »

OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder  more »

Code of Business Conduct and Ethics

The Board has adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers (including our Chief Executive Officer, our Chief Financial Officer and our principal accounting officer) and employees.

Notice of Amendment:
On June 14, 2012, the Company’s Board of Directors amended its Code of Business Conduct and Ethics to, among other things, further define various transactions which would constitute a conflict of interest, include provisions prohibiting usurpation of corporate opportunities, impose requirements of fair dealing and confidentiality, and clarify various reporting procedures and obligations for responding to government investigations and media or public inquires.

  Click here for Code

Email  Sign up for email alerts